IL140698A0 - Immunological reagent specifically interacting with the extracellular domain of the human zeta chain - Google Patents

Immunological reagent specifically interacting with the extracellular domain of the human zeta chain

Info

Publication number
IL140698A0
IL140698A0 IL14069899A IL14069899A IL140698A0 IL 140698 A0 IL140698 A0 IL 140698A0 IL 14069899 A IL14069899 A IL 14069899A IL 14069899 A IL14069899 A IL 14069899A IL 140698 A0 IL140698 A0 IL 140698A0
Authority
IL
Israel
Prior art keywords
antibody
chain
nucleic acid
extracellular domain
zeta
Prior art date
Application number
IL14069899A
Original Assignee
Connex Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Connex Gmbh filed Critical Connex Gmbh
Publication of IL140698A0 publication Critical patent/IL140698A0/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Abstract

The present invention relates to a nucleic acid molecule comprising a nucleic acid sequence encoding at least one complementary determining region (CDR) of a variable region of an antibody, said antibody specifically interacting with the extracellular domain of the human zeta-chain, said antibody being obtainable by immunizing a rat with Jurkat cells and subsequently with a conjugate comprising a carrier molecule and a peptide comprising the 11 N-terminal amino acids of a the rat zeta-chain. Preferably, the (poly)peptide encoded by the nucleic acid molecule of the invention is a monospecific or bispecific antibody. The invention also relates to pharmaceutical compositions comprising i. a. the nucleic acid molecule or antibody of the invention as well as to kits comprising the aforementioned compounds. Finally, the invention relates to a method for the determination of zeta-chain or eta-chain expression on NK-cells, T-cells or precursors thereof employing the antibody of the invention.
IL14069899A 1998-07-10 1999-07-09 Immunological reagent specifically interacting with the extracellular domain of the human zeta chain IL140698A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP98112867 1998-07-10
PCT/EP1999/004838 WO2000003016A1 (en) 1998-07-10 1999-07-09 Immunological reagent specifically interacting with the extracellular domain of the human zeta chain

Publications (1)

Publication Number Publication Date
IL140698A0 true IL140698A0 (en) 2002-02-10

Family

ID=8232256

Family Applications (1)

Application Number Title Priority Date Filing Date
IL14069899A IL140698A0 (en) 1998-07-10 1999-07-09 Immunological reagent specifically interacting with the extracellular domain of the human zeta chain

Country Status (17)

Country Link
US (1) US20050163770A1 (en)
EP (1) EP1097210B1 (en)
JP (1) JP2002520021A (en)
KR (1) KR20010074697A (en)
CN (1) CN1230538C (en)
AT (1) ATE330012T1 (en)
AU (1) AU767443B2 (en)
CA (1) CA2335090A1 (en)
DE (1) DE69931926T2 (en)
ES (1) ES2267275T3 (en)
ID (1) ID28117A (en)
IL (1) IL140698A0 (en)
NO (1) NO20010148L (en)
NZ (1) NZ509232A (en)
PT (1) PT1097210E (en)
TR (1) TR200100039T2 (en)
WO (1) WO2000003016A1 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1605966A1 (en) * 2003-03-24 2005-12-21 TAP Pharmaceutical Products, Inc. Use of chemokine receptor agonists for stem cell transplantation
AU2004242847B2 (en) * 2003-05-31 2011-06-09 Amgen Research (Munich) Gmbh Pharmaceutical composition comprising a bispecific antibody for EpCAM
EP3157634B1 (en) 2014-06-23 2018-12-12 Bionomics, Inc. Antibodies that bind lgr4
TW201829463A (en) * 2016-11-18 2018-08-16 瑞士商赫孚孟拉羅股份公司 Anti-hla-g antibodies and use thereof
CN111808183B (en) * 2020-07-25 2022-07-08 北京吉尔麦迪生物医药科技有限公司 High-affinity SIRP alpha mutant targeting CD47 and fusion protein thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5260203A (en) * 1986-09-02 1993-11-09 Enzon, Inc. Single polypeptide chain binding molecules
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
WO1990015822A1 (en) * 1989-06-15 1990-12-27 Dana-Farber Cancer Institute Monoclonal antibody to intracellular epitope of human t cell receptor zeta chain and method of preparation
UA40577C2 (en) * 1993-08-02 2001-08-15 Мерк Патент Гмбх Bispecific antigen molecule for lysis of tumor cells, method for preparing of bispecific antigen molecule, monoclonal antibody (variants), pharmaceutical preparation, pharmaceutical kit for lysis of tumor cells (variants), method of lysis of tumor cells

Also Published As

Publication number Publication date
KR20010074697A (en) 2001-08-09
EP1097210B1 (en) 2006-06-14
NO20010148D0 (en) 2001-01-09
PT1097210E (en) 2006-09-29
CN1308675A (en) 2001-08-15
DE69931926D1 (en) 2006-07-27
NZ509232A (en) 2003-10-31
TR200100039T2 (en) 2001-05-21
CN1230538C (en) 2005-12-07
CA2335090A1 (en) 2000-01-20
AU767443B2 (en) 2003-11-13
DE69931926T2 (en) 2007-02-01
JP2002520021A (en) 2002-07-09
ES2267275T3 (en) 2007-03-01
EP1097210A1 (en) 2001-05-09
WO2000003016A1 (en) 2000-01-20
ATE330012T1 (en) 2006-07-15
ID28117A (en) 2001-05-03
AU4909199A (en) 2000-02-01
US20050163770A1 (en) 2005-07-28
NO20010148L (en) 2001-03-09

Similar Documents

Publication Publication Date Title
UA40621C2 (en) monoclonal antibody, hybridoma cell line, polypeptide (VARIANTS), THE DNa FRAGMENT (VARIANTS), PHARMACEUTICAL COMPOSITION, METHOD FOR preparation OF monoclonal antibody
SG156547A1 (en) Human monoclonal antibodies to ctla-4
WO1994029350A3 (en) Recombinant disulfide-stabilized polypeptide fragments having binding specificity
EP1878746A3 (en) Human monoclonal antibodies to epidermal growth factor receptor
HRP20050986A2 (en) Antibodies directed to monocyte chemo-attractant protein-1 (mcp-1) and uses thereof
EP2829549A3 (en) Hybrid and tandem expression of neisserial derived proteins
TW200634027A (en) Antibodies directed to angiopoietin-2 and uses thereof
WO2006050949A3 (en) Superagonistic anti-cd28 antibody
WO2006055704A3 (en) Antibodies directed to ten-m proteins and uses thereof
CA2122732A1 (en) Multivalent antigen-binding proteins
RS51829B (en) Human antibodies specific for interleukin 15 (il-15)
CA2130452A1 (en) Altered antibodies, products and processes relating thereto
UA83791C2 (en) Antibody to vla-1, pharmaceutical composition, containing thereof, and use of them for treatment individual having immunological disorder, mediated by vla-1
NZ602780A (en) Human antibodies that bind lymphocyte activation gene-3 (lag-3), and uses thereof
WO2003025015A3 (en) A soluble toll-like receptor
IL140698A0 (en) Immunological reagent specifically interacting with the extracellular domain of the human zeta chain
WO1999005270A3 (en) Crustacean antimicrobial peptides, called penaiedines
WO2022152144A9 (en) Cd73-binding protein and use thereof
CA2441187A1 (en) Acetyllysine-recognizing monoclonal antibody and process for producing the same
WO2003051913A3 (en) Antigens for actinobacillus pleuropneumoniae and methods thereof
RU2422528C2 (en) Dna coding modified antibody or compound with tpo agonist activity, method of producing them and animal cell or microorganism producing them
Yang et al. Preparation and characterization of β1‐bungarotoxin bispecific monoclonal antibody
WO2003025143A3 (en) Maxp1
HUP9902713A2 (en) Antigen binding fragments that specifically detect cancer cells, nucleotides encoding the fragments, and use thereof for the prophylaxis and detection of cancers